Factors associated with favourable pathological tumour response after neoadjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma
HPB · 2024
DOI: 10.1016/j.hpb.2024.09.002 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift HPB, 2024. Verfasst von James M Halle-Smith und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary and Pancreatic Surgery Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, Wes…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Neoadjuvant Therapy, Pancreatic Neoplasms, Pancreatectomy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: Pathological response of pancreatic ductal adenocarcinoma (PDAC) to neoadjuvant chemotherapy (NAT) has been associated with oncological outcome. The aim of the study was to investigate factors associated with favourable tumour regression in patients undergoing pancreatic resection for PDAC. METHODS: Patients who received NAT before undergoing PDAC resection at two institutions were reviewed. Tumour regression grading (TRG) was scored according to the College of American Pathologists (CAP) system. Interactions between chemotherapy, tumour and surgical factors with TRG were explored. RESULTS: 54 patients were identified, with 12 (22%) displaying a favourable response to NAT. The type of chemotherapy agent received, the number of cycles or a dose reduction during NAT course was not significantly different between the groups. The time from diagnosis to chemotherapy and time from end of chemotherapy to surgery were also similar between the groups. A favourable TRG was associated with greater disease-free survival median 33.2 months vs. 10.3 months; p = 0.0) but not overall survival (median 43.8 months vs. 32.3 months; p = 0.200), which may be due to small sample size. CONCLUSIONS: Chemotherapy factors were not significantly related to a favourable response to NAT. Future studies should seek to identify modifiable factors associated with a favourable TRG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Hepatobiliary and Pancreatic Surgery Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom; College of Medical and Dental Sciences, Un…
- Aston University, Birmingham, West Midlands, United Kingdom.
- Hepatobiliary and Pancreatic Surgery Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom.
- Hepatobiliary and Pancreatic Surgery Unit, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom.
Zitieren
APA
Halle-Smith, J. M., Leung, P., Hall, L., Aksin, M., van Laarhoven, S., Skipworth, J., Chatzizacharias, N., Brown, R. M., & Roberts, K. J. (2024). Factors associated with favourable pathological tumour response after neoadjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. HPB. https://doi.org/10.1016/j.hpb.2024.09.002
Vancouver
Halle-Smith JM, Leung P, Hall L, Aksin M, van Laarhoven S, Skipworth J, et al. Factors associated with favourable pathological tumour response after neoadjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. HPB. 2024. doi:10.1016/j.hpb.2024.09.002
BibTeX
@article{HalleSmith2024,
author = {Halle-Smith, James M and Leung, Prudence and Hall, Lewis and Aksin, Merve and van Laarhoven, Stijn and Skipworth, James and Chatzizacharias, Nikolaos and Brown, Rachel M and Roberts, Keith J},
title = {Factors associated with favourable pathological tumour response after neoadjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma},
journal = {HPB},
year = {2024},
doi = {10.1016/j.hpb.2024.09.002}
}
EUVIMED